相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Francois Bouzom et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Physiologically based pharmacokinetic (PBPK) modeling: It is here to stay!
Amin Rostami-Hodjegan et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice
Joseph A. Grillo et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events
Christopher L. Shaffer et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
From preclinical to human - prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example
Vikash Kumar Sinha et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies
Yuan Chen et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2012)
Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy
Khaled Abduljalil et al.
CLINICAL PHARMACOKINETICS (2012)
Transporter-Mediated Drug-Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies
K. Yoshida et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time-Dependent CYP3A Inhibitor
Md L. T. Vieira et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Physiologically Based Pharmacokinetics Joined With In Vitro-In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology
A. Rostami-Hodjegan
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Sex Differences in the Clearance of CYP3A4 Substrates: Exploring Possible Reasons for the Substrate Dependency and Lack of Consensus
Manoranjenni Chetty et al.
CURRENT DRUG METABOLISM (2012)
Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2
David R. Plowchalk et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions
Guillaume Baneyx et al.
FUTURE MEDICINAL CHEMISTRY (2012)
Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug-Drug Interactions
Maria Karlgren et al.
PHARMACEUTICAL RESEARCH (2012)
Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions
Manthena V. S. Varma et al.
PHARMACEUTICAL RESEARCH (2012)
Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities
Sumio Ohtsuki et al.
DRUG METABOLISM AND DISPOSITION (2012)
Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data
Hannah M. Jones et al.
DRUG METABOLISM AND DISPOSITION (2012)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients Expected Variations in Clearance
Cyrus Ghobadi et al.
CLINICAL PHARMACOKINETICS (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Transporter-Mediated Drug-Drug Interactions
L. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Interplay of Metabolism and Transport in Determining Oral Drug Absorption and Gut Wall Metabolism: A Simulation Assessment Using the “Advanced Dissolution, Absorption, Metabolism (ADAM)” Model
A. S. Darwich et al.
CURRENT DRUG METABOLISM (2011)
Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism
Kuan Gandelman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Effect of Microgravity on the Pharmacokinetics of Ibuprofen in Humans
Nasir Idkaidek et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development
Piet H. van der Graaf et al.
PHARMACEUTICAL RESEARCH (2011)
Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake
Mikko Niemi et al.
PHARMACOLOGICAL REVIEWS (2011)
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
Helen E. Cubitt et al.
XENOBIOTICA (2011)
Modeling and predicting drug pharmacokinetics in patients with renal impairment
Karen Rowland Yeo et al.
Expert Review of Clinical Pharmacology (2011)
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling Two Cytochrome P450 3A4 Substrates Coadministered with Ketoconazole or Verapamil
Nathalie Perdaems et al.
CLINICAL PHARMACOKINETICS (2010)
A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2010)
The International Transporter Consortium: A Collaborative Group of Scientists From Academia, Industry, and the FDA
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism
Jianghong Fan et al.
CURRENT DRUG METABOLISM (2010)
Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator
Jakob Jornil et al.
DRUG METABOLISM AND DISPOSITION (2010)
Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
Ying-Hong Wang
DRUG METABOLISM AND DISPOSITION (2010)
Theoretical Considerations on Quantitative Prediction of Drug-Drug Interactions
Akihiro Hisaka et al.
DRUG METABOLISM AND PHARMACOKINETICS (2010)
Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam
Karen Rowland Yeo et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2010)
Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans
Takao Watanabe et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Drug-Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro-In Vivo Correlation Using Digoxin as a Probe Drug
K. S. Fenner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Towards a Quantitative Framework for the Prediction of DDIs Arising from Cytochrome P450 Induction
L. M. Almond et al.
CURRENT DRUG METABOLISM (2009)
Prediction of Human Drug-Drug Interactions from Time-Dependent Inactivation of CYP3A4 in Primary Hepatocytes Using a Population-Based Simulator
Lilly Xu et al.
DRUG METABOLISM AND DISPOSITION (2009)
Quantitative Prediction of in Vivo Profiles of CYP3A4 Induction in Humans from in Vitro Results with a Reporter Gene Assay
Masanari Kozawa et al.
DRUG METABOLISM AND DISPOSITION (2009)
Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite
Xin Zhang et al.
DRUG METABOLISM AND DISPOSITION (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
Masoud Jamei et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
Physiologically based pharmacokinetics (PBPK)
Pascal Espie et al.
DRUG METABOLISM REVIEWS (2009)
Quantitative Evaluation of Pharmacokinetic Inhibition of CYP3A Substrates by Ketoconazole: A Simulation Study
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells
Masahiro Tsuda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions;: predictions of compounds as objects of interaction
Kuresh A. Youdim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Maraviroc:: in vitro assessment of drug-drug interaction potential
Ruth Hyland et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Physiology-Based Simulations of a Pathological Condition Prediction of Pharmacokinetics in Patients with Liver Cirrhosis
Andrea N. Edginton et al.
CLINICAL PHARMACOKINETICS (2008)
General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information
Yoshiyuki Ohno et al.
CLINICAL PHARMACOKINETICS (2008)
Cytochrome P450 turnover: Regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions
Jiansong Yang et al.
CURRENT DRUG METABOLISM (2008)
Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction
Magang Shou et al.
DRUG METABOLISM AND DISPOSITION (2008)
A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2008)
Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling
F. Bouzom et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2008)
A regulatory viewpoint on transporter-based drug interactions
L. Zhang et al.
XENOBIOTICA (2008)
Multiple inhibition mechanisms and prediction of drug-drug interactions: Status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions
Laura K. Hinton et al.
PHARMACEUTICAL RESEARCH (2008)
Physiologically based approaches towards the prediction of pharmacokinetics:: in vitro-in vivo extrapolation
Stefan S. De Buck et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Role of OATP transporters in the disposition of drugs
Mikko Niemi
PHARMACOGENOMICS (2007)
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers
Y. Y. Lau et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application
Gemma L. Dickinson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver
Zoe E. Barter et al.
CURRENT DRUG METABOLISM (2007)
Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
Michaela Vossen et al.
THEORETICAL BIOLOGY AND MEDICAL MODELLING (2007)
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs
Stefan Willmann et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
Whole-body physiologically based pharmacokinetic models
Ivan Nestorov
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2007)
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects
Norio Yasui-Furukori et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Prediction of in vivo drug clearance from in vitro data.: II:: Potential inter-ethnic differences
S. Inoue et al.
XENOBIOTICA (2006)
The impact of in vitro binding on in vitro -: In vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions
K Grime et al.
CURRENT DRUG METABOLISM (2006)
The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions
RS Obach et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children
Trevor N. Johnson et al.
CLINICAL PHARMACOKINETICS (2006)
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
E. M. Howgate et al.
XENOBIOTICA (2006)
Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2006)
Changes in liver volume from birth to adulthood: A meta-analysis
TN Johnson et al.
LIVER TRANSPLANTATION (2005)
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro:: Effect of fibrates and rifampicin
LI Kajosaari et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2005)
Cyclosporine markedly raises the plasma concentrations of repaglinide
LI Kajosaari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes
RJ Riley et al.
DRUG METABOLISM AND DISPOSITION (2005)
In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: Prediction of nonstationary pharmacokinetics and drug interaction magnitude
K Venkatakrishnan et al.
DRUG METABOLISM AND DISPOSITION (2005)
Non-linear mixed effects modeling -: From methodology and software development to driving implementation in drug development science
G Pillai et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2005)
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo
DM Jonker et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Power, selection bias and predictive performance of the population pharmacokinetic covariate model
J Ribbing et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2004)
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
M Niemi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites
YH Wang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors
NJ Proctor et al.
XENOBIOTICA (2004)
Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: What have we learned?
SM Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The effects of dose staggering on metabolic drug-drug interactions
JS Yang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
M Niemi et al.
DIABETOLOGIA (2003)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide
V Hatorp et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine
KM Bertelsen et al.
DRUG METABOLISM AND DISPOSITION (2003)
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
DJ Belle et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Rifampin decreases the plasma concentrations and effects of repaglinide
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers
A Hemeryck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
分享论文
